Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Windward Bio Group AGWWB · filed Nov 18, 2026

Accession no.
0000947871-26-001038
Filed
Nov 18, 2026, 5:08 PM ET
Trade date
Nov 16, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market purchases total $20.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director, 10% Owner
OrbiMed Capital GP IX LLCCIK 0001920574Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2026Common SharesPPurchaseAcquired+1,176,471$17.00+$20,000,0071,708,103Indirect
Nov 16, 2026Common SharesCConversionAcquired+3,561,936–F4–5,270,039Indirect
Nov 16, 2026Common SharesCConversionAcquired+1,611,008–F4–6,881,047Indirect
Nov 16, 2026Common SharesMOption exerciseAcquired+216,668$0.02F5+$4,333.367,097,715Indirect
Nov 16, 2026Common SharesFTax withholdingDisposed−232$17.00−$3,9447,097,483Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 16, 2026Common SharesCConversionDisposed−3,561,936$0.00$00Indirect
Nov 16, 2026Common SharesCConversionDisposed−1,611,008$0.00$00Indirect
Nov 16, 2026Common SharesMOption exerciseDisposed−216,668$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.

Referenced by the price of 2 transactions in Table I.

F5

The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)